STVNHealthcare · Medical Instruments & SuppliesThe 13 Wall Street analysts covering Stevanato Group SpA hold a median 12-month price target of $25 — +24.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 3 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Stevanato Group SpA on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (81): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (43): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (22): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on STVN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +24.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Sept 2026 | UBS | Maintains | Neutral | $28 → $23 |
| 16 June 2026 | TD Cowen | Initiates | Buy | — |
| 2 June 2026 | Wolfe Research | Assumes | Outperform | $21 |
| 6 Mar 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 5 Mar 2026 | Citigroup | Maintains | Buy | — |
| 5 Mar 2026 | Keybanc | Maintains | Overweight | — |
| 2 Dec 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 11 Nov 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 7 Mar 2025 | UBS | Maintains | Neutral | — |
| 13 Dec 2024 | B of A Securities | Maintains | Buy | — |
| 13 Dec 2024 | Wolfe Research | Initiates | Outperform | — |
| 3 Dec 2024 | Morgan Stanley | Assumes | Equal-Weight | $24 → $23 |
| 7 Aug 2024 | Citigroup | Maintains | Buy | — |
| 15 July 2024 | Morgan Stanley | Maintains | Equal-Weight | — |
| 22 Apr 2024 | Morgan Stanley | Maintains | Equal-Weight | — |
| 25 Mar 2024 | Stephens & Co. | Reiterates | Overweight | — |
| 1 Nov 2023 | Jefferies | Downgrade | Hold | — |
| 1 Nov 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
| 26 Sept 2023 | Stephens & Co. | Initiates | Overweight | — |
| 19 Sept 2023 | CJS Securities | Initiates | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. STVN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 5 Oct 2026, Stevanato Group SpA returned −22.5% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 21% of US stocks
Cheaper than 27% of US stocks
Cheaper than 30% of US stocks
Cheaper than 16% of US stocks
Higher than 46% of US stocks
Higher than 19% of US stocks
Higher than 32% of US stocks
Higher than 75% of US stocks
Higher than 72% of US stocks
Higher than 61% of US stocks
Higher than 79% of US stocks
Higher than 55% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Stevanato Group SpA has a market value of $5.5B and an enterprise value of $6.6B.
Revenue in the twelve months to 30 June 2026: $1.2B. The latest quarter grew 7.8% year on year.
Net income over the same four quarters: $134.6M, a 11.0% net margin.
Diluted earnings per share, trailing twelve months: $0.48.
Free cash flow in the twelve months to 30 June 2026: −$30.7M.
Trailing P/E: 35.4×; forward P/E: 24.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 1.23%, paying out 11% of earnings.
Stevanato Group SpA employs 6,010 people — $204K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Stevanato Group SpA — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Stevanato Group S.p.A. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha.
Why it matters — A transcript of Stevanato's presentation gives investors and watchers direct insight into the company's messaging and priorities shared with the investment community.
The Baron Global Durable Advantage ETF reported its Q2 2026 portfolio activity, initiating new positions in Broadcom, Samsung Electronics, and INNIO, adding to 36 existing holdings, and exiting investments in Indutrade, HDFC Bank, and Wix to reallocate capital.
Why it matters — The item does not mention Stevanato Group, so it offers no direct insight into the fund's stance on the company, though its reallocation decisions could signal broader shifts in the portfolio.
Stevanato Group announced it will participate in two upcoming investor conferences: the Morgan Stanley Annual Global Healthcare Conference in New York on September 15 and the BofA Global Healthcare Conference on September 22. The company stated this in a press release from its Piombino Dese, Italy headquarters.
Why it matters — STVN watchers may follow these appearances as opportunities for the company to present its drug containment, delivery, and diagnostic solutions to the investment community at major healthcare conferences.
Stevanato Group is transitioning from a pharmaceutical glass supplier into an integrated drug containment and delivery platform, with its Alina injector seeing commercial adoption. High-value solutions now account for 45% of revenue, growing 16% year-over-year, supported by capacity investments in Fishers and Latina and a portfolio shift toward premium offerings.
Why it matters — STVN watchers would care because the validated commercial adoption of Alina and the shift toward higher-margin integrated offerings signal a durable transformation toward premium, higher-margin customer relationships and potential operating leverage.
Stevanato Group reported second-quarter 2026 revenue growth of 8%, driven by demand for higher-value drug containment and delivery products that lifted profitability. The company also updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary.
Why it matters — STVN watchers would care because the quarter shows growth and improved profitability from higher-value products, while the revised full-year outlook reflects a structural change from the Balda C. Brewer divestiture.
The 13 Wall Street analysts covering Stevanato Group SpA have a median 12-month price target of $25, with estimates ranging from $20 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Stevanato Group SpA, 9 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Stevanato Group SpA 68 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Oct 2026, Stevanato Group SpA ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (81 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +24.7% from the last close, and Ticker Nerd's factor model ranks Stevanato Group SpA 68 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Stevanato Group SpA publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $32 over the next 12 months.
Stevanato Group SpA returned -22.5% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Stevanato Group S.p.A. is an Italy-based healthcare company that provides integrated solutions for the pharmaceutical, biotechnology, and life sciences industries.
The most recent item we track (Seeking Alpha, 15 Sept 2026): "Stevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript". Stevanato Group S.p.A. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha.
Stevanato Group S.p.A. is an Italy-based healthcare company that provides integrated solutions for the pharmaceutical, biotechnology, and life sciences industries. The company focuses on drug containment, drug delivery, and diagnostic solutions, supplying products and services used across development, clinical, and commercial stages of the drug life cycle. Its portfolio includes containment systems such as vials, cartridges, syringes, and ampoules, alongside drug delivery devices, diagnostic consumables, analytical services, and medical devices. Stevanato Group also offers engineering capabilities through visual inspection, assembling, packaging, and glass-forming machinery, supporting manufacturing and packaging operations for biopharma customers. Headquartered in Piombino Dese, Italy, the company serves a global customer base across multiple healthcare and diagnostic markets.
CEO Mr. Franco Stevanato · 6,010 employees · Italy · https://www.stevanatogroup.com
